epinamics – Drug delivery expertise from Germany

epinamics is a Berlin-based, privately owned research and development company, focusing on a patent protected drug delivery technology for dermal and transdermal applications of pharmaceutical and cosmeceutical products.

The polymer-based Liqui-Patch® is an invisible film-forming technology that can be combined with a broad range of (active) pharmaceutical ingredients. It is a unique platform technology that serves key patient needs of convenience, tolerability and safety in drug application.

Next to providing the actual drug delivery technology, epinamics is lending its pharmaceutical research and development expertise to support your company in getting innovative products to market. A team of industry experts will guide you from concept stage all the way to a fully approved product.

We would be very pleased to hear from you.


Wolfgang Kehr, MD, PhD

Wolfgang Kehr gained more than 35 years of experience in leading positions in research, development, marketing and sales in the pharmaceutical industry, both in the United States and Europe.

At Schering AG he was in charge of global research of the pharmaceutical division and later headed the strategic business unit oncology and dermatology. At Berlex Laboratories, Inc. he was Vice President of Business Development and later General Manager of the cardiovascular and CNS Therapeutics Business. In his last position at Schering AG he was heading the dermatology unit which was spun out in 2005 as Intendis GmbH, with Wolfgang Kehr as President and CEO.

Since 2010 Prof. Dr. Wolfgang Kehr is CEO of epinamics GmbH.

Hans-Michael Thiede, MD

Hans-Michael Thiede’s scientific career started during the 1970s at Schering AG, where he developed his significant bioanalytical skills in toxicology and neuropharmacology.

From 1981 to 1991 he acquired extensive clinical experience in internal medicine, particularly in nephrology and cardiovascular diseases at the Charité – Campus Benjamin-Franklin. As the head of the local catecholamine laboratory, he investigated the role of catecholamine metabolism in essential hypertension which led to a number of bioanalytical innovations.

Hans-Michael Thiede developed a number of highly sensitive methods for the measurement of efficacy of active pharmaceutical ingredients. He continues his work as CEO at Thanares GmbH which he founded in Dresden in 2001 and which he later moved to Potsdam in 2007.

Since 2010 Hans-Michael Thiede is a partner and Chief Scientific Officer at epinamics GmbH.

Franziska Pruin, PhD

Franziska Pruin studied chemistry in Potsdam and holds a PhD from University of Zurich. Franziska´s experience in research and development ranging from nanoscience, analytical chemistry to galenic formulation. Within the last years, she gained extensive experiences as project manager in the team of Explicat Pharma GmbH in Munich working for the galenic development of several international projects with special emphasis to analytical questions.

In beginning of 2018 Franziska joined epinamics as head of project management. Franziska Pruin has significant expertise and experience in planning, coordination and execution of international projects as well as in preparation of regulatory submissions to authorities.


Jonathan Turner, PhD

Jonathan Turner studied pharmacology and physiology and holds a PhD from St. Andrews. Jon has extensive industry experience in Pharma, Biotech and Finance. He was Global Director of Discovery Alliances at AstraZeneca PLC (UK) and Corporate Head of Pharmaceutical Licensing at Boehringer Ingelheim (Germany).

From 2012 to 2014 he was CEO of Caprotec Bioanalytics GmbH (Germany). Since 2016 Jon is Senior Partner at Portus Corporate Finance GmbH (Germany), responsible for M&A, successions and company founding for the Life Sciences industry. At epinamics Jon serves as an independent advisor focusing on Business Development and Finance.

Jost-Tilo Gehrke, PhD

Jost-Tilo Gehrke has a degree in business administration and systems science. He started his career in 1994 as financial controlling trainee at Gillette Europe in London. Thereafter, he worked as marketing controller and product manager for Gillette Germany. In 1999, Jost-Tilo moved to Novartis as marketing manager for the OTC-division, responsible for the buildup and management of global brands like Voltaren, Otrivin and Nicotinell.

As Global Head of Marketing, he joined Schering’s dermatology spin-off Intendis in 2005 where he was in charge of process planning, portfolio restructuring and strategic management of global brands in the area of Eczema, Acne, Psoriasis and Rosacea.

Since 2013, Jost-Tilo serves as advisor to epinamics focusing on Business development and Marketing.